![Canadian Collaborative Research Network](http://media.vumedi.com/thumbs/channel_logo/2022/4/fdd25600-406a-4039-adbd-ed6417b2a508.jpeg.150x105_q85_autocrop_double_scale_upscale_version-0.2.jpg)
9 others would like to attend.
Register Now
Event info
OVERVIEW
The program will discuss key clinical trial findings presented at the European Society of Cardiology Congress. The program format will engage participants in an interactive discussion regarding trial result implications.
Topics:
- DELIVER – Does dapagliflozin improve outcomes in HFpEF? PERSPECTIVE – Does sacubitril/valsartan affect cognitive function in heart failure?
- PACIFIC Trials – What is the role of new factor Xia inhibitors in stroke and ACS?
- FOURIER OLE – What are the long-term safety data for PCSK9 inhibitors?
- ALL-HEART – Does allopurinol improve cardiovascular outcomes?
- SECURE – Is there a role for a polypill in secondary prevention? And more!
LEARNING OBJECTIVES
Following participation in this program, participants will be able to:
- Identify the clinical implications of the new data presented at ESC 2022
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice
For more information please visit the official event page.
Faculty
-
Milan Gupta
Co-Chair
-
Narendra Singh
Co-Chair
-
Michelle O'Donoghue
Co-Chair
Course Syllabus
Click HERE to view the syllabus
9 others would like to attend.
Register Now
Login to view comments.
Click here to Login